Table 2.
Brain regions with significant flow–metabolism dissociation during levodopa treatment
| Coordinatesa |
Zmax | CMRb |
CBFc |
|||||
|---|---|---|---|---|---|---|---|---|
| x | y | z | LD (OFF) | LD (ON) | LD (OFF) | LD (ON) | ||
| Putamen/GP | −30 | −8 | 2 | 4.82**** | 2.01 (0.05) | 1.89 (0.05)††† | 1.70 (0.02) | 1.80 (0.04)††† |
| 32 | −4 | −2 | 3.63** | 2.05 (0.05) | 1.95 (0.05)† | 1.78 (0.03) | 1.85 (0.04)† | |
| Thalamus | 12 | −22 | 0 | 3.05* | 1.88 (0.04) | 1.80 (0.03)† | 1.81 (0.03) | 1.86 (0.03)† |
| Subthalamic nucleus | 10 | −10 | −4 | 2.88* | 1.49 (0.04) | 1.44 (0.03)†† | 1.62 (0.03) | 1.67 (0.03)† |
| Dorsal pons | 6 | −34 | −32 | 4.85*** | 1.36 (0.04) | 1.32 (0.03)† | 1.61 (0.03) | 1.74 (0.04)††† |
aMontreal Neurological Institute (MNI) standard space.
bGlobally normalized CMR for glucose (mean ± SE) in each VOI (see Materials and Methods).
cGlobally normalized CBF (mean ± SE) in each VOI (see Materials and Methods).
Significant flow–metabolism dissociation (SPM interaction analysis): *p < 0.001, uncorrected; **p < 0.05, extent corrected; ***p < 0.005, ****p < 0.001, cluster corrected with voxel-level familywise error correction (p < 0.05).
Significant ON–OFF differences (paired t test): †p < 0.05; ††p < 0.01; †††p < 0.001.